Investigational drug · Phase 2
ADC
Also called: Antibody-drug conjugate, ADCE-D01
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Prostate Cancer Castration-resistant Prostate Cancer, Breast Cancer, Colo-rectal Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 11, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
851
Any phase or sponsor naming "ADC"
First trial start
2023
Nov 7, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ADC", any sponsor or status.
Conditions studied
As listed on its trial records.
- Prostate Cancer Castration-resistant Prostate Cancer
- Breast Cancer
- Colo-rectal Cancer
- Lung Cancer (Non-Small Cell)
- Pancreas Cancer, Duct Cell Adenocarcinoma
- Cancer
- Metastatic Soft Tissue Sarcoma
- Unresectable Soft Tissue Sarcoma
Approved drugs for the same conditions: Breast cancer · Prostate cancer · Sarcoma · Oncology · Kidney and urology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "ADC" as an intervention, largest first.
Central South UniversityAcademic, hospital or other
NCT05349383 · 24,618 participants · Start Apr 22, 2022 · Primary completion May 22, 2022
Drug: Antibody-Drug Conjugate; Antineoplastic and immunomodulating agents other than Antibody-Drug Conjugate · For: Sepsis (SMQ); Opportunistic Infections; Agranulocytosis
Sites: Changsha, China
- Survival Outcomes of Lung CancerRecruiting
Hunan Province Tumor HospitalAcademic, hospital or other
NCT03647098 · 20,000 participants (planned) · Start Aug 1, 2018 · Primary completion Dec 31, 2028
Drug: Treatment · For: Lung Cancer
Sites: Changsha, China
- A Multicenter Phase III Clinical Study and Translational Research on Adaptive Neoadjuvant Therapy of De-escalation and Escalation for HER2-Positive Breast Cancer Based on Multi-Omics Response Evaluation ModelPivotal-lookingNot yet recruiting
Cancer Institute and Hospital, Chinese Academy of Medical SciencesAcademic, hospital or other
NCT07239271 · 2,000 participants (planned) · Start Nov 16, 2025 · Primary completion Dec 2027
Drug: The control group; Adaptive therapy of de-escalation and escalation based on imaging and molecular analysis for predicting response · For: Patients With HER2-positive Breast Cancer (BC) Suitable for Neoadjuvant Therapy
- A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast CancerPivotal-lookingActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT06112379 · 1,902 participants · Start Nov 14, 2023 · Primary completion Nov 20, 2028
Drug: Dato-DXd; Durvalumab and 8 more · For: Breast Cancer
Sites: Daphne, Alabama; Prescott, Arizona; Jonesboro, Arkansas · 283 sites in all
- A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and NivolumabPivotal-lookingRecruiting
National Cancer Institute (NCI)NIH
NCT05675410 · 1,875 participants (planned) · Start May 11, 2023 · Primary completion Apr 28, 2031
Drug: Bleomycin Sulfate; Brentuximab Vedotin and 11 more · For: Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 419 sites in all
BioNTech SEIndustry
NCT07070232 · 1,438 participants (planned) · Start Aug 12, 2025 · Primary completion Mar 2028
Drug: BNT326; Pumitamig and 2 more · For: Advanced Solid Tumor
Sites: Phoenix, Arizona; San Francisco, California; Hartford, Connecticut · 79 sites in all
- Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)Active, not recruiting
Klus Pharma Inc.Industry
NCT04152499 · 1,410 participants · Start Feb 28, 2020 · Primary completion Nov 30, 2025
Drug: SKB264 · For: Epithelial Ovarian Cancer; Gastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma and 7 more
Sites: Glendale, California; Los Angeles, California; Sarasota, Florida · 109 sites in all
- Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic AlterationsPivotal-lookingActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT05687266 · 1,350 participants · Start Dec 29, 2022 · Primary completion Nov 1, 2027
Drug: Datopotamab deruxtecan; Durvalumab and 5 more · For: NSCLC
Sites: Phoenix, Arizona; Tucson, Arizona; Hot Springs, Arkansas · 254 sites in all
- DC Vaccine Therapy Combined With Cytokine-Induced Killer Cell in TreatingPivotal-lookingNot yet recruiting
The First People's Hospital of ChangzhouAcademic, hospital or other
NCT02487550 · 1,200 participants (planned) · Start Aug 2015 · Primary completion Jul 2028
Drug: DC-CIK; IL-2/IFN-α · For: Renal Neoplasma
- A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)Pivotal-lookingActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT05629585 · 1,174 participants · Start Nov 28, 2022 · Primary completion Sep 1, 2027
Drug: Dato-DXd; Durvalumab and 2 more · For: Breast Cancer
Sites: Gilbert, Arizona; Tucson, Arizona; Hot Springs, Arkansas · 276 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Targeting triple-negative breast cancer: Molecular basis and emerging antibody-drug conjugate strategies.
Feng H, Padala C, Liu B · Biochim Biophys Acta Mol Basis Dis 2027
- Bulk and single-cell transcriptomics identify tumor-specific epithelial PSAT1 as a ferroptosis-associated therapeutic target in cervical cancer.
Tabassum Z, Hadi K, Sudheer A, et al. · Comput Biol Chem 2027
- Advanced Diffusion MRI in the Human Brain: Microstructure Imaging and Structural Connectivity.
Tayebi M, Saludar CJ, Mezzano S, et al. · Methods Mol Biol 2027
- CRISPR-Cas9 mediated adiA knockout in Hafnia paralvei: Implications for agmatine production and acid stress survival in a fermented dairy matrix.
Casado A, Wellner SM, Quirós A, et al. · Food Microbiol 2027
- SeqEyes: An Open-Source Toolbox for Synchronized Waveform/Trajectory Visualization in Pulseq.
Yong X, Liu Z, Dong Y, et al. · Magn Reson Med 2027
- A novel frequency tracking method based on improved ESC control method for megasonic cleaning system.
Peng T, Wu Y, Yang L, et al. · Ultrasonics 2027
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.